Sagimet Biosciences Inc Series A (SGMT)

$7.29 +0.13 (1.82%)
Market Cap 237.09M
Revenue (ttm) 0.00
Net Income (ttm) -45.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 318,200
Avg Vol 581,072
Day's Range N/A - N/A
Shares Out 32.52M
Stochastic %K 73%
Beta 3.23
Analysts Strong Sell
Price Target $25.50

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
MickeyAsh
MickeyAsh Oct. 3 at 10:47 PM
$SGMT I will gamble, I have an order for 500. If it fills it fills if not oh well.
0 · Reply
MickeyAsh
MickeyAsh Oct. 3 at 10:15 PM
$SGMT I've been watching this stock and what doesn't make any sense at all is institutions pumping it yet none of them are buying it and it seems to be more selling from institutions than anything
0 · Reply
biostock
biostock Oct. 3 at 7:51 PM
$SGMT 5 or 25 $SPY $QQQ
0 · Reply
John___wick44
John___wick44 Oct. 3 at 5:16 PM
$SGMT joke of a price. Absolute shit show that this trades at 7. should be bought out today for 40-50. let alone ne trading at 12-14 minimum. huge disconnect
0 · Reply
Amanda2024
Amanda2024 Oct. 3 at 3:38 PM
$SGMT as long as green
0 · Reply
rational1
rational1 Oct. 3 at 12:47 PM
$SGMT Canaccord reiterates buy
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 12:26 PM
Canaccord Genuity updates rating for Sagimet Biosciences ( $SGMT ) to Buy, target set at 28.
0 · Reply
lookgoodplaygood22
lookgoodplaygood22 Oct. 1 at 3:48 PM
$GLMD $GNPX $GTBP $PDSB $SGMT gold mine.
0 · Reply
CalculatedSwing
CalculatedSwing Oct. 1 at 3:03 PM
$GLMD 🚀 $GLMD soaring +10% on epic proxy news! CEO Baharaff locked in with equity grants & performance bonuses tied to big milestones—NASH pipeline looking hot! Newbies, this is your chance to go all in for the moon! 🌕 Tagging the degens, leg up time: $SGMT $GTBP $PDSB $GNPX #Biotech #AllIn
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 1 at 11:27 AM
$SGMT Sagimet Doses First Participants In Phase 1 Pharmacokinetic Trial Of Combination Of Oral Once-Daily FASN Inhibitor, Denifanstat, And THR-β Agonist, Resmetirom; Topline Data Expected In H1 2026
0 · Reply
Latest News on SGMT
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 17, 2025, 7:00 AM EDT - 18 days ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 10, 2025, 7:00 AM EDT - 25 days ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 10:05 PM EDT - 27 days ago

Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development

Aug 29, 2025, 11:19 AM EDT - 5 weeks ago

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 5 weeks ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 13, 2025, 7:30 AM EDT - 7 weeks ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 1:45 PM EDT - 4 months ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Jun 4, 2025, 5:00 AM EDT - 4 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 22, 2025, 8:00 AM EDT - 4 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 6:00 AM EDT - 5 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 7 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 11, 2025, 8:00 AM EDT - 7 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Mar 7, 2025, 4:27 PM EST - 7 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14, 2024, 3:56 PM EST - 11 months ago

Sagimet: More Than Just A MASH Drug Development Biotech

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Nov 12, 2024, 6:30 AM EST - 11 months ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 18, 2024, 3:10 PM EDT - 1 year ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jul 31, 2024, 12:24 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 25, 2024, 8:58 PM EST - 1 year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 24, 2024, 1:55 PM EST - 1 year ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 23, 2024, 5:45 PM EST - 1 year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 11:10 PM EST - 1 year ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 1 year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Dec 4, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 28, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 13, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Nov 10, 2023, 8:30 AM EST - 2 years ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Oct 24, 2023, 11:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Oct 18, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sep 27, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sep 27, 2023, 2:48 PM EDT - 2 years ago

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 21, 2023, 4:02 PM EDT - 2 years ago

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

MickeyAsh
MickeyAsh Oct. 3 at 10:47 PM
$SGMT I will gamble, I have an order for 500. If it fills it fills if not oh well.
0 · Reply
MickeyAsh
MickeyAsh Oct. 3 at 10:15 PM
$SGMT I've been watching this stock and what doesn't make any sense at all is institutions pumping it yet none of them are buying it and it seems to be more selling from institutions than anything
0 · Reply
biostock
biostock Oct. 3 at 7:51 PM
$SGMT 5 or 25 $SPY $QQQ
0 · Reply
John___wick44
John___wick44 Oct. 3 at 5:16 PM
$SGMT joke of a price. Absolute shit show that this trades at 7. should be bought out today for 40-50. let alone ne trading at 12-14 minimum. huge disconnect
0 · Reply
Amanda2024
Amanda2024 Oct. 3 at 3:38 PM
$SGMT as long as green
0 · Reply
rational1
rational1 Oct. 3 at 12:47 PM
$SGMT Canaccord reiterates buy
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 12:26 PM
Canaccord Genuity updates rating for Sagimet Biosciences ( $SGMT ) to Buy, target set at 28.
0 · Reply
lookgoodplaygood22
lookgoodplaygood22 Oct. 1 at 3:48 PM
$GLMD $GNPX $GTBP $PDSB $SGMT gold mine.
0 · Reply
CalculatedSwing
CalculatedSwing Oct. 1 at 3:03 PM
$GLMD 🚀 $GLMD soaring +10% on epic proxy news! CEO Baharaff locked in with equity grants & performance bonuses tied to big milestones—NASH pipeline looking hot! Newbies, this is your chance to go all in for the moon! 🌕 Tagging the degens, leg up time: $SGMT $GTBP $PDSB $GNPX #Biotech #AllIn
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 1 at 11:27 AM
$SGMT Sagimet Doses First Participants In Phase 1 Pharmacokinetic Trial Of Combination Of Oral Once-Daily FASN Inhibitor, Denifanstat, And THR-β Agonist, Resmetirom; Topline Data Expected In H1 2026
0 · Reply
highnihilism
highnihilism Sep. 30 at 11:12 AM
$SGMT Sagimet Biosciences: 51 trades, $29K vs $84K avg (0.34x). $24K calls / $4K puts. $TNYA Tenaya Therapeutics: 66 trades, $25K vs $13K avg (1.86x). $24K calls / $0.40K puts. $MGA Magna International: 63 trades, $28K vs $1.03M avg (0.03x !!!). $24K calls / $4K puts. $PTC PTC: 9 trades, $24K vs $71K avg (0.33x). $24K calls / $0.17K puts.
0 · Reply
rational1
rational1 Sep. 29 at 7:11 PM
$SGMT no volume in today's weakness. Just MM gaming the system (again)
1 · Reply
John___wick44
John___wick44 Sep. 29 at 5:35 PM
$SGMT next leg down coming. see where shorts take it this time
0 · Reply
biostock
biostock Sep. 29 at 10:42 AM
$SGMT will benefit from $MLTX ACNE disappointment. $SPY $QQQ
0 · Reply
Norny44
Norny44 Sep. 26 at 7:03 PM
$SGMT been watching this slowly creeping up again. Time to buy back in me thinks 🤔
0 · Reply
shibadad
shibadad Sep. 25 at 3:02 PM
$SGMT The stock has been trending higher on increasing volume. Feels like someone is accumulating shares at these levels. Or could be shorts changing their mind.... Short interest popped to 3.1M shares as of 9/15/25 which coincided with the recent low.
0 · Reply
JoeBio
JoeBio Sep. 24 at 6:04 PM
$SGMT Sold majority of my shares from buys in the low 3's. Kept 20k shares as part of profit....Will look to reenter if opportunity arises before EOY!. May all your trades and investments prove profitable!
1 · Reply
biostock
biostock Sep. 24 at 4:42 PM
$SGMT Soon chase will ensue. $SPY $QQQ
1 · Reply
John___wick44
John___wick44 Sep. 24 at 2:53 PM
$SGMT BO 38 or higher. cannot believe the joke of a price this is. simply comical
2 · Reply
aletz
aletz Sep. 24 at 8:50 AM
$SGMT Just a question, what's up with MASH pipeline? Planning for Phase 3? looking for a partner? EOP2 Meeting done? I was intrigued by the data, but cannot seem to find any plan.
2 · Reply
himsssss
himsssss Sep. 23 at 8:42 PM
My picks have been on fire. $MTSR told you to buy at $21+ , now bought out by $PFE $SGMT called to buy this under $4 trade all the way to $10.xX $SRPT called to buy at 11-13.50 traded all the way to 21.xx. Still holding $IDYA as I can see a run into $40 range.
0 · Reply
JoeBio
JoeBio Sep. 22 at 6:11 PM
$SGMT @testius Could not agree more. Thinking of selling my core with profit of over 200K to buy back in couple of months at lower price....May all your trades and investment be profitable!
0 · Reply